ICICI Bank has come out stronger in the last one and half year with strong asset quality in unsecured loans, NIMs higher than the pre-Covid rate cycle and solid liabilities profile while growing the domestic loan book higher than the system growth. ICICI Bank balance sheet profile is strong - (1) CET-1 is adequate at 16.3% (2) Provision buffer is best-in-class at ~1% of loans despite higher than system loan growth and (3) LCR is adequate at 122.7%. Opex intensity is likely to reduce going ahead. We expect NIM’s to contract by 14-17bps in Q2FY26 and normalisation of credit costs to 55-65bps over FY26 & FY27. We expect ICICI to deliver ROAs of 2.2% over FY26-27E leading to sustenance of premium valuation multiple over its peers.
| CMP (Rs) | Target (Rs) | Upside |
|---|---|---|
| ₹1,380 | ₹1,700 | 23% |
| Bloomberg Code | ICICIBC IN |
|---|---|
| Curr Shares O/S (mn)* | 7148.6 |
| Mkt Cap (Rsbn/USDmn) | 9,867.3 / 111,243 |
| 52 Wk H / L (Rs)* | 1500 / 1186 |
| 5 Year H / L (Rs)* | 1500 / 388 |
| Daily Vol. 3M Avg. (‘000) | 10009 |
Source: ACE Equity, MNCL Research
| (%) | 1M | 6M | 1Yr |
|---|---|---|---|
| ICICI | -1.7 | 6.1 | 11.0 |
| NIFTY | 1.3 | 12.9 | 1.1 |
Source: ACE Equity, MNCL Research
| (%) | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|
| FII | 46.8 | 45.8 | 45.7 |
| DII./Govt. | 44.1 | 45.1 | 45.2 |
| Public | 9.1 | 9.1 | 9.1 |
Source: ACE Equity, MNCL Research
CASA growth in Q1FY26 remained best-in-class at 9% yoy vs. 2%/4%/6% for Axis/Kotak/ HDFC. Bank has very low reliance on wholesale deposits.
SME book has been growing at a high rate and we expect it to grow at over 18-20% for next few years. Business banking is a high yield book with decent asset quality resulting in high ROAs. We expect Unsecured segments like Credit Cards and Personal Loans to also pick up going ahead driving overall retail book. Overall we expect loan growth of 12-13% over FY26-27, higher than the system growth of ~10-11%.
ICICI Pru AMC’s IPO is around the corner which could result in unlocking some value given that bank holds 51% stake in it. We attribute Rs 55/share each to its life and general insurance subsidiaries in SOTP. Yes Bank stake sale would also boost profitability and book value in Q2FY26.
ICICI continues to deliver superior and consistent performance. ICICI Bank’s management focus on profitability over balance sheet growth has held the bank in steady ship vs peers who have lagged in both balance sheet and profitability due to asset quality and margins. We value ICICI Bank banking business at 2.7x FY27 BV and its stake in Subsidiaries at 250/share to arrive at our fair value of 1700/share over next 1 year.
| Y/E Mar (Rs mn) | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|
| NII | 7,43,057 | 8,11,644 | 8,58,607 | 9,76,446 |
| YoY (%) | 19.5 | 9.2 | 5.7 | 13.7 |
| PPOP | 5,81,307 | 6,72,988 | 7,15,553 | 8,32,574 |
| YoY (%) | 18.4 | 15.7 | 6.3 | 16.3 |
| PAT | 4,08,882 | 4,72,269 | 4,75,217 | 5,61,154 |
| YoY (%) | 28.1 | 15.5 | 0.62 | 18.0 |
| BVPS (Rs)* | 333 | 406 | 458 | 523 |
| Y/E Mar | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|
| NIMs (%) | 4.52 | 4.25 | 4.00 | 4.05 |
| ROE (%) | 19.0 | 18.1 | 15.4 | 16.1 |
| ROA (%) | 2.4 | 2.4 | 2.1 | 2.2 |
| P/B (x) | 3.71 | 3.05 | 2.52 | 2.21 |
Source: Company ICICI Bank Ltd, MNCL Research
| Stock Details | Industry | Buying Range (₹) | CMP* (₹) | Target Price (₹) | Upside Potential % |
|---|---|---|---|---|---|
| Bharat Electronics Ltd | Defence | 407-420 | 414 | 463 | 12% |
| Brigade Enterprises Ltd | Real-estate | 920-970 | 943 | 1341 | 42% |
| Clean Science & Technology Ltd | Specialty Chemical | 1045-1100 | 1072 | 1220 | 14% |
| Elecon Engineering Company Ltd | Capital Goods | 540-580 | 557 | 733 | 32% |
| ICICI Bank Ltd | BFSI | 1360-1400 | 1380 | 1700 | 23% |
| National Aluminium Company Ltd | Metals | 215-235 | 224 | 280 | 25% |
| Sai Life Sciences Ltd | Healthcare | 840-885 | 861 | 1055 | 22% |
| TBO Tek Ltd | Hospitality | 1520-1600 | 1562 | 1853 | 19% |
| TCPL Packaging Ltd | Packaging | 3300-3500 | 3402 | 4303 | 26% |
| Vesuvius India Ltd | Metals | 490-520 | 505 | 585 | 16% |
| Windlas Biotech Ltd | Healthcare | 890-940 | 915 | 1225 | 34% |
*Closing Price as on 10-10-2025
Turn the Diwali lights into wealth lights – Open your MNCL Demat Account today!
Disclaimer - Investments in securities market are subject to market risk, read all the related document carefully before investing.
https://www.mnclgroup.com/
Empower your finances with ReSach – the stock trading apptrusted by serious investors. Whether you're planning to invest in stocks, explore commodity trading, or need a financial advisor to guide you, Resach brings it all under one platform.
Start trading today with ReSach and unlock seamless investing on the go.
Name of the Company has changed from Networth Stock Broking Limited to Monarch Networth Capital Limited upon Certification of Incorporation received from Registrar of Companies, Mumbai vide certificate dated 13th October, 2015.
If you are not satisfied with the resolution provided, you can lodge your complaint online at: https://scores.sebi.gov.in/link
In case of grievance client can log on to the SMART ODR Portal, if they are unsatisfied with the response provided by us. Your attention is drawn to the SEBI circular no. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, on “Online Resolution of Disputes in the Indian Securities Market”.
Purchase of REs only gives buyer the right to participate in the ongoing Rights Issue of the concerned company by making an application with requisite application money or renounce the REs before the issue closes. REs which are neither subscribed by making an application with requisite application money nor renounced, on or before the Issue closing date shall lapse and shall be extinguished after the Issue closing date. Please check your dp account for further details.
Please do not share your online trading password with anyone as this could weaken the security of your account and lead to unauthorized trades or losses.
Monarch Networth Capital Limited (‘MNCL’) | CIN No.: L64990GJ1993PLC120014
Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53, Zone 5, Road-5E, Gift City, Gandhinagar - 382050, Gujarat
Ahmedabad
“Monarch House”, Opp Prahladbhai Patel garden, Near Ishwar Bhuvan, Commerce Six Roads, Navrangpura, Ahmedabad - 380009
Mumbai
Monarch Networth Capital Limited, G Block, Laxmi Tower, B Wing, 4th Floor, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
Email for Grievance: grievances@mnclgroup.com
Investors are requested to note that Stock broker (Monarch Networth Capital Ltd) is permitted to receive money from investors through designated bank accounts only named as Up streaming Client Nodal Bank Account (USCNBA). Stock broker (Monarch Networth Capital Ltd) is also required to disclose these USCNB accounts to Stock Exchange. Hence, you are requested to use following USCNB accounts only (Click to View) for the purpose of dealings in your trading account with us. The details of these USCNB accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker".
Mechanism for addressing grievances and information about SCORES.
Mechanism for addressing grievances and information about SCORES.
Monarch Networth Capital Limited (‘MNCL’) | CIN No.: L64990GJ1993PLC120014
(As per LODR Regulations and Companies Act, 2013)
Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances : Mr. Nitesh Tanwar
Monarch Networth Capital Limited
Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53, Zone 5, Road-5E, Gift City, Gandhinagar - 382050, Gujarat
Ahmedabad
“Monarch House”, Opp Prahladbhai Patel garden, Near Ishwar Bhuvan, Commerce Six Roads, Navrangpura, Ahmedabad – 380009
Mumbai
Monarch Networth Capital Limited, G Block, Laxmi Tower, B Wing, 4th Floor, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
Phone: 022 - 66476400 / 66476405
Email: cs@mnclgroup.com
Email for Grievance: cs@mnclgroup.com
Listing of Equity Shares on Stock Exchange at
BSE
NSE
(Formerly known as Link Intime India Private Limited)
For any queries related to broking please contact helpdesk@mnclgroup.com.
‘Investments in securities market are subject to market risks, read all the related documents carefully before investing.’
